Current Heart Failure Reports

, Volume 9, Issue 4, pp 319–327

Anemia and Iron Deficiency in Heart Failure

Pathophysiology of Myocardial Failure (IS Anand, Section Editor)

Abstract

Anemia is a common comorbidity in heart failure (HF), and is associated with increased morbidity and mortality. However, it remains unclear whether anemia is merely a marker of poor prognosis or whether anemia itself confers risk. The pathogenesis of anemia in HF is multifactorial. Iron deficiency also confers risk in HF, either with or without associated anemia, and treatment of iron deficiency improves the functional status of patients with HF. An ongoing large clinical trial studying the use of darbepoetin–alfa in patients with anemia and systolic HF is expected to provide information that should improve our understanding of anemia in HF.

Keywords

Heart failure Anemia Iron deficiency Erythropoietin stimulating agents Intravenous iron 

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Roger VL, et al. Heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation. 2012;125(1):e2–e220.PubMedCrossRefGoogle Scholar
  2. 2.
    Silverberg DS, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 2000;35(7):1737–44.PubMedCrossRefGoogle Scholar
  3. 3.
    Henke M, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double–blind, placebo-controlled trial. Lancet. 2003;362(9392):1255–60.PubMedCrossRefGoogle Scholar
  4. 4.
    Leyland-Jones B, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol. 2005;23(25):5960–72.PubMedCrossRefGoogle Scholar
  5. 5.
    Singh AK, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085–98.PubMedCrossRefGoogle Scholar
  6. 6.
    Pfeffer MA, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019–32.PubMedCrossRefGoogle Scholar
  7. 7.
    Anand IS, et al. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation. 2005;112(8):1121–7.PubMedCrossRefGoogle Scholar
  8. 8.
    O'Meara E, et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation. 2006;113(7):986–94.PubMedCrossRefGoogle Scholar
  9. 9.
    Adams Jr KF, et al. Prospective assessment of the occurrence of anemia in patients with heart failure: results from the Study of Anemia in a Heart Failure Population (STAMINA-HFP) Registry. Am Heart J. 2009;157(5):926–32.PubMedCrossRefGoogle Scholar
  10. 10.
    Kosiborod M, et al. Anemia and outcomes in patients with heart failure: a study from the National Heart Care Project. Arch Intern Med. 2005;165(19):2237–44.PubMedCrossRefGoogle Scholar
  11. 11.
    Go AS, et al. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. Circulation. 2006;113(23):2713–23.PubMedCrossRefGoogle Scholar
  12. 12.
    Dunlay SM, et al. Anemia and heart failure: a community study. Am J Med. 2008;121(8):726–32.PubMedCrossRefGoogle Scholar
  13. 13.
    Tang WH, Yeo PS. Epidemiology of anemia in heart failure. Heart Fail Clin. 2010;6(3):271–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Groenveld HF, et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol. 2008;52(10):818–27.PubMedCrossRefGoogle Scholar
  15. 15.
    Berry C, et al. The prevalence, nature, and importance of hematologic abnormalities in heart failure. Am Heart J. 2006;151(6):1313–21.PubMedCrossRefGoogle Scholar
  16. 16.
    Tang WH, et al. Evaluation and long-term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure. J Am Coll Cardiol. 2008;51(5):569–76.PubMedCrossRefGoogle Scholar
  17. 17.
    Ishani A, et al. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J Am Coll Cardiol. 2005;45(3):391–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Komajda M, et al. The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. Eur Heart J. 2006;27(12):1440–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Salisbury AC, Kosiborod M. Outcomes associated with anemia in patients with heart failure. Heart Fail Clin. 2010;6(3):359–72.PubMedCrossRefGoogle Scholar
  20. 20.
    Peterson PN, et al. Association of longitudinal measures of hemoglobin and outcomes after hospitalization for heart failure. Am Heart J. 2010;159(1):81–9.PubMedCrossRefGoogle Scholar
  21. 21.
    •• Waldum B, et al. Baseline anemia is not a predictor of all-cause mortality in outpatients with advanced heart failure or severe renal dysfunction. Results from the Norwegian Heart Failure Registry. J Am Coll Cardiol. 2012;59(4):371–8. This registry of 4144 chronic heart failure patients demonstrated that anemia was strongly associated with increased mortality. Yet, the study identified two sub-populations of patients in whom anemia was not a predictor of all-cause mortality. PubMedCrossRefGoogle Scholar
  22. 22.
    Kalra PR, et al. Haemoglobin concentration and prognosis in new cases of heart failure. Lancet. 2003;362(9379):211–2.PubMedCrossRefGoogle Scholar
  23. 23.
    Maraldi C, et al. Anemia, physical disability, and survival in older patients with heart failure. J Card Fail. 2006;12(7):533–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Young JB, et al. Relation of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE-HF registry). Am J Cardiol. 2008;101(2):223–30.PubMedCrossRefGoogle Scholar
  25. 25.
    Anand IS. Pathophysiology of anemia in heart failure. Heart Fail Clin. 2010;6(3):279–88.PubMedCrossRefGoogle Scholar
  26. 26.
    Jankowska EA, Ponikowski. Molecular changes in myocardium in the course of anemia or iron deficiency. Heart Fail Clin. 2010;6(3):295–304.PubMedCrossRefGoogle Scholar
  27. 27.
    Le Jemtel TH, Arain S. Mediators of anemia in chronic heart failure. Heart Fail Clin. 2010;6(3):289–93.PubMedCrossRefGoogle Scholar
  28. 28.
    Freudenthaler SM, et al. Angiotensin II increases erythropoietin production in healthy human volunteers. Eur J Clin Invest. 1999;29(10):816–23.PubMedCrossRefGoogle Scholar
  29. 29.
    Opasich C, et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J. 2005;26(21):2232–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Belonje AM, et al. Erythropoietin in chronic heart failure. Congest Heart Fail. 2007;13(5):289–92.PubMedCrossRefGoogle Scholar
  31. 31.
    Belonje AM, et al. Endogenous erythropoietin and outcome in heart failure. Circulation. 2010;121(2):245–51.PubMedCrossRefGoogle Scholar
  32. 32.
    van der Meer P, et al. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol. 2004;44(1):63–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol. 2006;17(1):17–25.PubMedCrossRefGoogle Scholar
  34. 34.
    Testa M, et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol. 1996;28(4):964–71.PubMedCrossRefGoogle Scholar
  35. 35.
    Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011–23.PubMedCrossRefGoogle Scholar
  36. 36.
    Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation. 2003;107(2):223–5.PubMedCrossRefGoogle Scholar
  37. 37.
    • Okonko DO, et al. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol. 2011;58(12):1241–51. This paper demonstrates how the use of three frequently available indices (TSAT, ferritin, and TIBC) permits the biochemically meaningful discrimination between absolute iron deficiency, functional iron deficiency( ACD), and coexisting absolute + functional iron deficiency. PubMedCrossRefGoogle Scholar
  38. 38.
    Nanas JN, et al. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol. 2006;48(12):2485–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Anand IS. Heart failure and anemia: mechanisms and pathophysiology. Heart Fail Rev. 2008;13(4):379–86.PubMedCrossRefGoogle Scholar
  40. 40.
    Mrug M, et al. Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest. 1997;100(9):2310–4.PubMedCrossRefGoogle Scholar
  41. 41.
    Terrovitis JV, et al. Prevalence and prognostic significance of anemia in patients with congestive heart failure treated with standard vs high doses of enalapril. J Heart Lung Transplant. 2006;25(3):333–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Androne AS, et al. Hemodilution is common in patients with advanced heart failure. Circulation. 2003;107(2):226–9.PubMedCrossRefGoogle Scholar
  43. 43.
    Marques JS. Perspectives for the treatment of anemia in heart failure: is there a role for vasopressin antagonists? Congest Heart Fail. 2012;18(1):1–3.PubMedCrossRefGoogle Scholar
  44. 44.
    van Veldhuisen DJ, et al. Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. Nat Rev Cardiol. 2011;8(9):485–93.PubMedCrossRefGoogle Scholar
  45. 45.
    Van Wyck DB, et al. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int. 2005;68(6):2846–56.PubMedCrossRefGoogle Scholar
  46. 46.
    Besarab A, Horl WH, Silverberg D. Iron metabolism, iron deficiency, thrombocytosis, and the cardiorenal anemia syndrome. Oncologist. 2009;14 Suppl 1:22–33.PubMedCrossRefGoogle Scholar
  47. 47.
    van der Meer P, et al. Erythropoietin treatment in patients with chronic heart failure: a meta-analysis. Heart. 2009;95(16):1309–14.PubMedCrossRefGoogle Scholar
  48. 48.
    Drueke TB, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355(20):2071–84.PubMedCrossRefGoogle Scholar
  49. 49.
    • Szczech LA, et al. A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. Kidney Int. 2010;77(3):239–46. This secondary analysis of the CHOIR trial did not demonstrate an increased risk of adverse events for patients with a history of heart failure who were treated with the higher hemoglobin target of 13.5 g/l as compared to those with a target of 11.3 g/l. PubMedCrossRefGoogle Scholar
  50. 50.
    • Desai A, et al. Impact of erythropoiesis-stimulating agents on morbidity and mortality in patients with heart failure: an updated, post-TREAT meta-analysis. Eur J Heart Fail. 2010;12(9):936–42. This meta-analysis of ESA treatment trials that included the subroup of patients with heart failure in the TREAT trial demonstrated that ESAs had a neutral effect on heart failure outcomes. PubMedCrossRefGoogle Scholar
  51. 51.
    Ghali JK, et al. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation. 2008;117(4):526–35.PubMedCrossRefGoogle Scholar
  52. 52.
    Toblli JE, et al. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol. 2007;50(17):1657–65.PubMedCrossRefGoogle Scholar
  53. 53.
    Okonko DO, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol. 2008;51(2):103–12.PubMedCrossRefGoogle Scholar
  54. 54.
    Anker SD, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361(25):2436–48.PubMedCrossRefGoogle Scholar
  55. 55.
    Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Br J Haematol. 2008;141(1):14–31.PubMedCrossRefGoogle Scholar
  56. 56.
    Rastogi S, et al. Darbepoetin-alpha prevents progressive left ventricular dysfunction and remodeling in nonanemic dogs with heart failure. Am J Physiol Heart Circ Physiol. 2008;295(6):H2475–82.PubMedCrossRefGoogle Scholar
  57. 57.
    Hedley BD, Allan AL, Xenocostas A. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression. Clin Cancer Res. 2011;17(20):6373–80.PubMedCrossRefGoogle Scholar
  58. 58.
    Tanaka T, Nangaku M. Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agents. Exp Cell Res. 2012.Google Scholar
  59. 59.
    Parsa CJ, et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest. 2003;112(7):999–1007.PubMedGoogle Scholar
  60. 60.
    Solomon SD, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010;363(12):1146–55.PubMedCrossRefGoogle Scholar
  61. 61.
    Aapro M. et al. Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer. Br J Cancer. 2012.Google Scholar
  62. 62.
    Barbera L, Thomas G. Erythropoiesis stimulating agents, thrombosis and cancer. Radiother Oncol. 2010;95(3):269–76.PubMedCrossRefGoogle Scholar
  63. 63.
    Tang YD, Katz SD. The prevalence of anemia in chronic heart failure and its impact on the clinical outcomes. Heart Fail Rev. 2008;13(4):387–92.PubMedCrossRefGoogle Scholar
  64. 64.
    McMurray JJ, et al. Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. Eur J Heart Fail. 2009;11(8):795–801.PubMedCrossRefGoogle Scholar
  65. 65.
    van der Meer P, et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol. 2005;46(1):125–33.PubMedCrossRefGoogle Scholar
  66. 66.
    Hirata A, et al. Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J Am Coll Cardiol. 2006;48(1):176–84.PubMedCrossRefGoogle Scholar
  67. 67.
    Palazzuoli A, et al. Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. Am Heart J. 2007;154(4):645 e9–15.CrossRefGoogle Scholar
  68. 68.
    Brines M, et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci U S A. 2004;101(41):14907–12.PubMedCrossRefGoogle Scholar
  69. 69.
    Fiordaliso F, et al. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc Natl Acad Sci U S A. 2005;102(6):2046–51.PubMedCrossRefGoogle Scholar
  70. 70.
    Anand IS. Anemia and chronic heart failure implications and treatment options. J Am Coll Cardiol. 2008;52(7):501–11.PubMedCrossRefGoogle Scholar
  71. 71.
    •• Jankowska EA, et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J. 2010;31(15):1872–80. Prevalence of iron deficiency in patients with heart failure is typically discussed in the context of anemia. To our knowledge, this is the first study to provide an estimate of the prevalence of iron deficiency in patients with chronic systolic heart failure with or without anemia. Iron deficiency, regardless of the anemia status was shown to be an independent predictor of adverse outcomes. PubMedCrossRefGoogle Scholar
  72. 72.
    Dong F, et al. Dietary iron deficiency induces ventricular dilation, mitochondrial ultrastructural aberrations and cytochrome c release: involvement of nitric oxide synthase and protein tyrosine nitration. Clin Sci (Lond). 2005;109(3):277–86.CrossRefGoogle Scholar
  73. 73.
    Silverberg DS, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol. 2001;37(7):1775–80.PubMedCrossRefGoogle Scholar
  74. 74.
    Mancini DM, et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation. 2003;107(2):294–9.PubMedCrossRefGoogle Scholar
  75. 75.
    Palazzuoli A, et al. Beta-erythropoietin effects on ventricular remodeling, left and right systolic function, pulmonary pressure, and hospitalizations in patients affected with heart failure and anemia. J Cardiovasc Pharmacol. 2009;53(6):462–7.PubMedCrossRefGoogle Scholar
  76. 76.
    Ponikowski P, et al. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2007;49(7):753–62.PubMedCrossRefGoogle Scholar
  77. 77.
    van Veldhuisen DJ, et al. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J. 2007;28(18):2208–16.PubMedCrossRefGoogle Scholar
  78. 78.
    Parissis JT, et al. Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am Heart J. 2008;155(4):751 e1–7.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.MetroHealth Campus of Case Western Reserve UniversityClevelandUSA

Personalised recommendations